Accessibility Menu
Knight Therapeutics logo

Knight Therapeutics(OTC) KHTRF

Market Cap$683.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+26%
5 Year+60%
1 Year+49%
1 Month-2%
$6.96
+2.81%
+0.19Today
Knight Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 6.962026-08-20
Knight Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.88%USD 6.702026-08-13
1 month-1.62%USD 7.072026-07-21
3 month+15.81%USD 6.012026-05-22
Year to date+60%USD 4.352025-12-31
1 year+49.36%USD 4.662025-08-20
3 year+110.27%USD 3.312023-08-15
5 year+60%USD 4.352021-08-18
Since inception+25.81%USD 5.532014-04-03

Knight Therapeutics Financials at a Glance

Market Cap

$683.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$547.75M

Net Income (TTM)

CA$14.69M

EPS (TTM)

$0.11

P/E Ratio

63.74

Dividend

$0.00

Beta (Volatility)

0.06 (Low)

Price

$6.96

Volume

287

Open

$6.96

Previous Close

$6.96

Daily Range

$6.96 - $6.96

52-Week Range

$4.07 - $7.40

Estimated Earnings Date

Nov 5, 2026

KHTRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Knight Therapeutics

Knight Therapeutics Inc. is a specialized pharmaceutical company focused on the development, acquisition, and distribution of a diverse range of pharmaceutical products and medical devices. The company operates primarily in Canada and Latin America, offering innovative treatments for various medical conditions.

Products and Services
  • Offers treatments for cancers, including Nerlynx and Tafasitamab
  • Provides medications for chronic conditions like diabetes and multiple myeloma
  • Engages in financing life science ventures and capital allocation
Growth Outlook
  • Strong product pipeline with multiple therapies targeting critical health issues
  • Expansion into new markets expected to drive revenue growth
  • Strategic partnerships may enhance product offerings and market reach
Financial Highlights
  • Recent quarterly revenue of 144.2 million CAD, showing resilience
  • Trailing twelve months (TTM) revenue of 580.9 million CAD, indicating stability
  • Current ratio of 2.28, reflecting strong liquidity position
Knight Therapeutics Inc. has established itself as a key player in the pharmaceutical industry, with a robust portfolio of products aimed at addressing significant health challenges. The company's focus on innovation and strategic partnerships positions it well for future growth. Recent financial performance highlights a solid revenue base and a strong liquidity position, which may appeal to potential investors looking for opportunities in the healthcare sector. The ongoing expansion into new markets and the development of new therapies further enhance the company's growth prospects.
AI Generated • Aug 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

830

CEO

Samira Sakhia, MBA

Website

www.gud-knight.com

Headquarters

Montreal, QC H4M 2P2, CA

KHTRF Financials

Key Financial Metrics (TTM)

Gross Margin

36.88%

Operating Margin

4.82%

Net Income Margin

2.72%

Return on Equity

1.91%

Return on Capital

-0.26%

Return on Assets

1.42%

Earnings Yield

1.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$683.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.23M

Volume

287

Avg. Volume

8.81K

Financials (TTM)

Gross Profit

CA$215.46M

Operating Income

CA$26.42M

EBITDA

CA$81.38M

Operating Cash Flow

CA$114.92M

Capital Expenditure

-CA$4.87M

Free Cash Flow

CA$110.05M

Cash & ST Invst.

CA$121.17M

Total Debt

CA$34.28M

Knight Therapeutics Performance Analysis

Knight Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 225,496,18916.1%
20232023-12-31CAD 243,166,7557.8%
20242024-12-31CAD 271,032,41811.5%
20252025-12-31CAD 322,115,28218.8%
Knight Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.4%
Q42025-12-319.3%
Q12026-03-3111.9%
Q22026-06-30-3.1%
Knight Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.20N/A
20232023-12-31CAD -0.12-41.9%
20242024-12-31CAD 0.03N/A
20252025-12-31CAD -0.04N/A
Knight Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3070.7%
Q42025-12-31334.1%
Q12026-03-3145.7%
Q22026-06-30-126.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$144.21M

+34.3%

Gross Profit

CA$69.62M

+55.3%

Gross Margin

48.27%

N/A

Market Cap

$683.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$823.73K

N/A

Employees

830

N/A

Net Income

-CA$3.36M

+73.4%

EBITDA

CA$15.03M

+1468.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$121.17M

+4.1%

Total Debt

CA$34.28M

-67.3%

Accounts Receivable

CA$125.82M

+16.8%

Inventory

CA$144.57M

-2.7%

Long Term Debt

CA$14.56M

-82.4%

Short Term Debt

CA$19.72M

-11.2%

Return on Assets

1.42%

N/A

Return on Invested Capital

3.06%

N/A

Free Cash Flow

CA$28.90M

+692.7%

Operating Cash Flow

CA$29.52M

+45.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGYTFAllergy Therapeutics plc
$0.15+0.00%
VRNOFVerano Holdings Corp.
$1.30+8.33%
PTCHFPureTech Health plc
$1.57+0.00%
VHIBFVitalhub Corp.
$5.80+4.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About KHTRF

What is the current price of Knight Therapeutics?

Knight Therapeutics is trading at $6.96 per share.

What is the 52-week range for Knight Therapeutics?

Over the past 52 weeks, Knight Therapeutics has traded between $4.07 and $7.40.

How much debt does Knight Therapeutics have?

As of the most recent reporting period, Knight Therapeutics reported total debt of CA$24.16M.

How much cash does Knight Therapeutics have on hand?

Knight Therapeutics reported CA$65.93M in cash and cash equivalents in its most recent financial results.

What is Knight Therapeutics’s dividend yield?

Knight Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services